sCR1sLe ameliorates ischemia/reperfusion injury in experimental lung transplantation.
BACKGROUND
The nonspecific immune response with activation of the complement system and polymorphonuclear leukocytes is important for the mediation of reperfusion injury after lung transplantation. In this study, we investigated the combined blockade of the complement system and leukocyte adhesion by a novel drug combining soluble complement receptor type 1 (sCR1, CD35) with the selectin ligand sialyl Lewis X (sLe(X), CD15s) synthesized to sCR1sLe(X). Both sCR1 and sCR1sLe(X) were supplied by AVANT Immunotherapeutics, Inc, Needham, Massachusetts.


METHODS
Orthotopic allogeneic single left lung transplantation was performed in male rats (Brown Norway to Fischer F344; n = 5 in all groups) after a total ischemic time of 20 hours. Recipients received either no specific treatment (control) or administration of sCR1 (10 mg/kg) or sCR1sLe(X) (10 mg/kg) 15 minutes before reperfusion by intracardiac injection. Twenty-four hours after reperfusion, the native contralateral lung was occluded to assess gas exchange of the graft only. In additional animals (5 per group), lung tissue was frozen 24 hours after reperfusion and assessed for myeloperoxidase activity as a measurement of neutrophil migration into the graft and thiobarbituric acid reactive substances to quantify lipid peroxidation.


RESULTS
Graft function as assessed by arterial PO (2) in recipients treated with sCR1sLeX was superior not only to that of controls (383 +/- 53 vs 56 +/- 7 mm Hg, P =. 000095) but also to that of animals treated with sCR1 (243 +/- 45 mm Hg, P =.031). This improvement was confirmed by significant reduction of neutrophil migration (0.33 +/- 0.05 vs control, 1.0 +/- 0.09 DeltaOD/mg/min, P =.0000024) and lipid peroxidation (6.2 +/- 0. 38 vs control, 10.6 +/- 0.54 pmol/g, P =.00021).


CONCLUSIONS
Our data indicate that combined inhibition of complement activation and leukocyte adhesion with sCR1sLe(X) reduces reperfusion injury significantly and that both mechanisms are effectively inhibited in this model.
Stammberger
U
U
Division of General Thoracic Surgery, University Hospital, Berne, Switzerland.
Hamacher
J
J
Hillinger
S
S
Schmid
R A
RA
D000818:Animals; D003167:Complement Activation / Q000187:drug effects / Q000276:immunology; D003169:Complement Inactivator Proteins / Q000276:immunology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology; D015227:Lipid Peroxidation / Q000187:drug effects / Q000276:immunology; D016040:Lung Transplantation / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D051379:Mice; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D051381:Rats; D011916:Rats, Inbred F344; D011951:Receptors, Complement / Q000276:immunology / Q000627:therapeutic use*; D015427:Reperfusion Injury / Q000209:etiology* / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D013997:Time Factors; D014184:Transplantation, Homologous
D003169:Complement Inactivator Proteins; D011951:Receptors, Complement; D017392:Thiobarbituric Acid Reactive Substances; C082885:soluble complement inhibitor 1